Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Uterine fibroids, also known as uterine leiomyomas, are the most common tumors affecting the female reproductive tract. These tumors disrupt the function of uterus and causes anemia, excess bleeding, and pelvic discomfort. There are various treatment options available for the treatment of the condition such as drug therapy and surgical procedure.

U.S. uterine fibroids treatment market is estimated to account for US$ 243.5 Mn in terms of value in 2020 and is expected to reach US$ 298.5 Mn by the end of 2027.

U.S. Uterine Fibroids Treatment Market: Drivers

High incidence of uterine fibroids among women is expected to propel growth of the U.S. uterine fibroids treatment market over the forecast period. For instance, according to the study, ‘A US population-based study of uterine fibroids diagnosis incidence, trends, and prevalence: 2005 through 2014’ published in October 2018, the incidence rates for fibroids diagnoses was 240.3 per 10,000 woman-years in 2014 in the age group 45–49 years.

Moreover, availability of effective therapies is also expected to aid in growth of the market. For instance, ulipristal acetate (UPA) is effective in reducing the symptoms due to uterine leiomyomata. UPA is approved for short?term use prior to surgery and longer?term use.

Hysterectomy held dominant position in the U.S. uterine fibroids treatment market in 2019, accounting for 79.0% share in terms of value, followed by myomectomy and endometrial ablation, respectively.

Figure 1. U.S. Uterine Fibroid Treatment Market Share (%), by Value, by Procedure Type, 2019

U.S. Uterine Fibroid Treatment  | Coherent Market Insights

U.S. Uterine Fibroids Treatment Market: Restraints

Complications associated with morcellators are expected to hinder growth of the U.S. uterine fibroids treatment market. Laparoscopic power morcellators are used in hysterectomy and myomectomy procedures for the treatment of uterine fibroids. However, power morcellators could cause complications such as metastatic leiomyosarcoma cancer.

Moreover, current treatments for fibroids are mainly surgical and expensive, which is also expected to limit growth of the market.

U.S. Uterine Fibroids Treatment Market: Opportunities 

Improved awareness and education regarding uterine fibroids treatment is expected to offer lucrative growth opportunities for players in the market. For instance, the study, ‘Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women’, published in November 2018, concluded that women with fibroids or symptoms suggestive of fibroids experience significant distress that reduces quality of life and that several many women are likely undiagnosed, which increases the need for improved awareness and education.

Moreover, uterine fibroids is a difficult condition to study. However, the burden of the condition is high, which increases the need for rigorous and innovative research related to the condition.

The U.S. uterine fibroids treatment market was valued at US$ 236.7 Mn in 2019 and is forecast to reach a value of US$ 298.5 Mn by 2027 at a CAGR of 3.0% between 2020 and 2027.

Figure 2. U.S. Uterine Fibroids Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

U.S. Uterine Fibroid Treatment  | Coherent Market Insights

Market Trends/Key Takeaways

Use of ulipristal acetate (UPA) may lead to drug?induced liver injury. However, this can be considered as a very rare idiosyncratic event. UPA should not be recommended to patients with liver anomalies or disorders.

The adoption of pharmacologic therapy is high in the U.S. for the treatment of uterine fibroids. For instance, according to the study, ‘Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women’, published in November 2018, 71% of uterine fibroids patients used pharmacologic therapy for symptom relief and 30% underwent surgical or procedural treatment.

U.S. Uterine Fibroids Treatment Market: Competitive Landscape

Major players operating in the U.S. uterine fibroids treatment market include, Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH.

U.S. Uterine Fibroids Treatment Market: Key Developments

Major players in the market are focused on R&D to expand their product portfolio. For instance, in April 2020, Sumitovant Biopharma Ltd. announced publication of abstracts from Myovant Sciences regarding the efficacy and safety of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids, in the journal Obstetrics & Gynecology.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in April 2018, CooperSurgical acquired the assets of The LifeGlobal Group and its affiliates, a leading global provider of in-vitro fertilization devices.

Uterine fibroid is the benign tumor of the woman’s uterus formed of smooth muscle that are found on the wall of the uterus i.e within the wall of uterine wall or can attach to the uterine wall. Uterine fibroid grow as a single tumor or in clusters and these uterine fibroid can lead to pelvic pain, excessive menstrual bleeding, and frequent urination. Uterine fibroids majorly develop in 50% of women, which have led to increased rate of hysterectomy i.e. removal of the uterus. Uterine fibroid is developed in women that often have a family history of fibroids. The uterine fibroid is formed and grown in response to the stimulation by hormone estrogen that is produced naturally in the body. Various types of uterine fibroid treatment are available in the market due to technological advancements, which include minimal invasive surgical treatment that help to control the growth of uterine fibroid. Uterine fibroid can be treated by both surgery and medications, the surgery include for treatment of uterine fibroid are hysterectomy, cryosurgery, myomectomy, uterine artery embolization, and MRI-guided high-intensity focused ultrasound.

Restraints of the U.S. Uterine Fibroid Treatment Market

Major factors hampering the growth of the U.S. uterine fibroid treatment market during the forecast period constitutes of risks associated with the use of morcellators, and high treatment costs.

Key features of the study:

  • This report provides in-depth analysis of the U.S. uterine fibroid treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the U.S. uterine fibroid treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The U.S. uterine fibroid treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the assistive reproductive technology market.

Detailed Segmentation

  • U.S. Uterine Fibroid Treatment Market, By Procedure Type:
    • Endometrial Ablation
    • MRI Guided Procedures
      • MRI-guided Percutaneous Laser Ablation
      • MRI-guided Transcutaneous Focused Ultrasound
    • Hysterectomy
      • Abdominal Hysterectomy
      • Vaginal Hysterectomy
      • Laparoscopic Hysterectomy
      • Robotic Hysterectomy
      • Hysteroscopic Morcellation
    • Myomectomy
      • Open Myomectomy
      • Laparoscopic Myomectomy
      • Robotic Myomectomy
    • Uterine Artery Embolization
    • Radiofrequency Ablation
    • Others
  • U.S. Uterine Fibroid Treatment Market, By End User:
    • Hospitals
    • Ambulatory Surgical Centers
  • Company Profiles
    • Blue Endo*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Boston Scientific Corporation
    • CooperSurgical, Inc.
    • KARL STORZ SE & Co. KG
    • Myovant Sciences (Sumitovant Biopharma Ltd.)
    • Halt Medical, Inc.
    • LiNA Medical USA
    • Merit Medical Systems
    • Olympus Corporation
    • Richard Wolf GmbH

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Procedure Type
      • Market Snippet, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. U.S. Uterine Fibroid Treatment Market, By Procedure Type, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Endometrial Ablation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • MRI Guided Procedures
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • MRI-guided Percutaneous Laser Ablation
        • MRI-guided Transcutaneous Focused Ultrasound
    • Hysterectomy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • Abdominal Hysterectomy
        • Vaginal Hysterectomy
        • Laparoscopic Hysterectomy
        • Robotic Hysterectomy
        • Hysteroscopic Morcellation
    • Myomectomy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • Open Myomectomy
        • Laparoscopic Myomectomy
        • Robotic Myomectomy
    • Uterine Artery Embolization
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Radiofrequency Ablation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  5. U.S. Uterine Fibroid Treatment Market, By End User, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Ambulatory Surgical Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
  6. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Blue Endo
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boston Scientific Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • CooperSurgical, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • KARL STORZ SE & Co. KG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Myovant Sciences (Sumitovant Biopharma Ltd.)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Halt Medical, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • LiNA Medical USA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merit Medical Systems
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Olympus Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Richard Wolf GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 15 market data tables and 25 figures on “Uterine Fibroid Treatment Market – U.S. forecast to 2027.

Frequently Asked Questions

The U.S. uterine fibroids treatment market was valued at US$ 236.7 Mn in 2019 and is forecast to reach a value of US$ 298.5 Mn by 2027 at a CAGR of 3.0% between 2020 and 2027.
Major factors driving the growth of U.S. uterine fibroid treatment market during the forecast period include high incidence among women, and technological advancements in medical devices.
Major factors hampering the growth of the U.S. uterine fibroid treatment market during the forecast period constitutes of risks associated with the use of morcellators, and high treatment costs.
Hysterectomy held dominant position in the U.S. uterine fibroids treatment market in 2019.
Hospitals held largest market share in U.S. uterine fibroid treatment market in 2019.
Some of the key players operating in the market are Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner